Suppliers / Zhejiang Bamboo Pharmaceuticals Co., Ltd

Zhejiang Bamboo Pharmaceuticals Co., Ltd

China 3 employees Updated 9 July 2026

Zhejiang Bamboo Pharmaceuticals Co., Ltd is an API manufacturer based in China. It holds 6 active US drug master files across a filed portfolio of 5 molecules. Its GMP standing is certified by US FDA and EMA. Its most recent recorded inspection, by US FDA, closed on 27 September 2024 as VAI.

6
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 27 September 2024 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Shaoxing, China Not on file
China, China 3019684157

What they file, and where

Molecule Regulators Docs
Pregabalin US FDA 2
Benzocaine US FDA 1
Gabapentin US FDA 1
Levocarnitine US FDA 1
Tranexamic Acid US FDA 1

Also appears on these molecule pages

Benzocaine API Gabapentin API Levocarnitine API Tranexamic Acid API Pregabalin API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1
EMA None 1

Questions about Zhejiang Bamboo Pharmaceuticals Co., Ltd

Does Zhejiang Bamboo Pharmaceuticals Co., Ltd hold a US DMF or a CEP?
Zhejiang Bamboo Pharmaceuticals Co., Ltd holds 6 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
Is Zhejiang Bamboo Pharmaceuticals Co., Ltd FDA-registered?
One site operated by Zhejiang Bamboo Pharmaceuticals Co., Ltd carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Zhejiang Bamboo Pharmaceuticals Co., Ltd's last inspection go?
The most recent inspection on record closed on 27 September 2024 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 1 inspection is on file.
Where does Zhejiang Bamboo Pharmaceuticals Co., Ltd manufacture?
2 registered sites are on record, in China (Shaoxing and China). Every site is listed on this page with the register it came from.
What does Zhejiang Bamboo Pharmaceuticals Co., Ltd make?
5 molecules are on record against Zhejiang Bamboo Pharmaceuticals Co., Ltd, including Pregabalin, Benzocaine, Gabapentin and Levocarnitine. Each links through to that molecule's full manufacturer list.
Which regulators recognise Zhejiang Bamboo Pharmaceuticals Co., Ltd's GMP?
Current GMP certificates are on record from US FDA and EMA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Bamboo Pharmaceuticals Co., Ltd comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 27 September 2024.

Comparable suppliers

Apitoria Pharma shares 1 molecule Hetero shares 1 molecule Olon shares 1 molecule Matrix Pharmacorp shares 1 molecule Granules India shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates